Roche posted a stronger-than-expected 2025 finish, with group sales up 7% at constant exchange rates to CHF 61.5 billion, pharma rising 9% on the back of Ocrevus, Hemlibra, Vabysmo, Xolair, and Phesgo, and diagnostics edging up 2% despite China headwinds. Core EPS grew 11% at constant exchange rates, IFRS net income rose sharply on base effects, and guidance points to mid single-digit sales and high single-digit EPS growth in 2026. The year also delivered meaningful pipeline progress: subcutaneous Lunsumio secured approvals in the US and EU for follicular lymphoma, Gazyva/Gazyvaro won EU approval for lupus nephritis, phase 3 readouts for giredestrant in early ER+ breast cancer and fenebrutinib across both relapsing and primary progressive MS moved the needle, and the dual GLP-1/GIP agonist CT‑388 showed 22.5% weight loss in phase 2. Roche also advanced 10 molecules into phase 3 and moved to complete its acquisition of 89bio.
The throughline is strategic: Roche is using modality and setting-of-care shifts to defend and extend its immunology and oncology franchises while building a credible cardiometabolic platform. The critical question for leadership teams is whether the combination of subcutaneous delivery, outpatient-compatible regimens, and high-value diagnostics can create durable access and margin advantages as payers tighten budgets and competitors converge on similar targets.
For patients and providers, the immediate impact is in time and place of care. Subcutaneous Lunsumio compresses chair time from hours to about a minute, potentially freeing infusion capacity and enabling community-based delivery for indolent lymphoma. In autoimmune nephritis, Gazyva’s EU approval opens a new standard-of-care path at risk of dialysis, expanding Roche’s renal footprint. In MS, positive late-stage data for the oral BTK inhibitor fenebrutinib in both relapsing and primary progressive disease sets up a franchise pivot that could partially cannibalize Ocrevus but expand total reach if disability outcomes and safety are compelling. Medical Affairs will need to translate these shifts into practice change through targeted education, infusion-to-injection transition pathways, and real-world studies that quantify resource utilization and adherence in decentralized settings. Payers will demand evidence that shorter administration and chemo-free combinations translate into lower total cost of care, not just convenience.
Competitive dynamics are sharpening in breast cancer and obesity. Giredestrant’s adjuvant win positions the first oral SERD with superior invasive disease-free survival against decades-old endocrine standards, with implications for guideline updates, sequencing with CDK4/6 inhibitors, and testing strategies. CT‑388’s weight-loss profile approaches class leaders, but Roche arrives late to an obesity market dominated by Lilly and Novo Nordisk. The 89bio acquisition adds FGF21 biology and a credible path in MASH/NASH, suggesting a cardiometabolic stack that spans weight, liver health, and cardiovascular risk. Differentiation will hinge on durability, tolerability at maintenance doses, manufacturing scalability, and outcomes that matter to payers, including NASH resolution and hard CV endpoints.
Diagnostics remains a ballast and a bridge. While China’s pricing reforms weighed on Asia-Pacific, Roche is leaning into high medical value and speed: CE marks for dengue antigen and BV/CV vaginitis testing, a CLIA‑waived Bordetella assay at the point of care, and an expanded automated mass spectrometry menu for therapeutic drug monitoring. The convergence of rapid decentralized testing with centralized sequencing and automation strengthens system stickiness and companion diagnostic synergies that can accelerate pharma uptake.
The next year is executional: can Roche convert subcutaneous oncology and autoimmune launches, MS readouts, and a cardiometabolic build-out into contracting wins and guideline traction before rivals entrench? A decisive proof point will be whether payers reward the infusion-to-injection shift with preferential access that turns convenience into measurable, budget-relevant value.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
